Sellas Fast Tracked for Treatment of Relapsed/Refractory Peripheral T-cell Lymphomas

 SLS009 Demonstrated Promising Efficacy in Phase 1 Study with 36.4% Clinical Response (ORR) in r/r Peripheral T-cell Lymphomas (PTCL); ORR in r/r PTCL Patients with Standard of Care is 25.8% -

- Fast Track Designation Accelerates SLS009's Path to U.S. FDA Submission for Treatment of r/r PTCL -

https://www.globenewswire.com/news-release/2023/10/30/2769302/0/en/SELLAS-Life-Sciences-Receives-Fast-Track-Designation-from-FDA-for-SLS009-for-Treatment-of-Relapsed-Refractory-Peripheral-T-cell-Lymphomas.html